Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16370866 | 1.00 | CYP2C19 (0.39) | CYP2C19ALDH1A1CYP3A4CYP2C9POLB | |
| SCHEMBL31012850 | 0.84 | SMN1; SMN2 (0.35) | CYP2C19ALDH1A1CYP2C9POLBSMN1; SMN2 | |
| SCHEMBL16391339 | 0.79 | POLB (0.41) | CYP2C19CYP3A4POLBATMF10 | |
| SCHEMBL23311802 | 0.78 | ALDH1A1 (0.36) | CYP2C19ALDH1A1CYP3A4CYP2C9POLB | |
| SCHEMBL4812312 | 0.73 | CYP2C19 (0.43) | CYP2C19ALDH1A1CYP3A4CYP2C9POLB | |
| SCHEMBL30727105 | 0.72 | GAA (0.35) | CYP2C19ALDH1A1CYP3A4CYP2C9POLB | |
| SCHEMBL30727104 | 0.72 | GAA (0.35) | CYP2C19ALDH1A1CYP3A4CYP2C9POLB | |
| SCHEMBL16391277 | 0.72 | CYP2C19 (0.40) | CYP2C19ALDH1A1CYP3A4CYP2C9POLB | |
| SCHEMBL875700 | 0.72 | CYP2C19 (0.40) | CYP2C19ALDH1A1CYP3A4CYP2C9POLB | |
| SCHEMBL15563930 | 0.72 | ALDH1A1 (0.39) | CYP2C19ALDH1A1CYP3A4CYP2C9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739680-A1 | SOLID FORMS OF TRPV4 ANTAGONISTS | Actio Biosciences, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250333403-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12391683-B2 | Therapeutic compounds and methods | ACTIO BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4551572-A1 | THERAPEUTIC COMPOUNDS AND METHODS | Actio Biosciences, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790051-A | Therapeutic compounds and methods | 爱克堤欧生物科学股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025014818-A1 | SOLID FORMS OF GSK2798745, A TRPV4 ANTAGONIST | ACTIO BIOSCIENCES, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240287055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11987577-B2 | Therapeutic compounds and methods | ACTIO BIOSCIENCES, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240076294-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2024011214-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333403-A1 | THERAPEUTIC COMPOUNDS AND METHODS | TRPV4, TRPV3, TRPV2 | CYP2C19 3788/4885ALDH1A1 2090/4885CYP3A4 1560/4885 |
| US-20240287055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | TRPV4, TRPV3, TRPV2 | CYP2C19 3788/4885ALDH1A1 2090/4885CYP3A4 1560/4885 |
| US-11987577-B2 | Therapeutic compounds and methods | TRPV4, TRPV3, TRPV2 | CYP2C19 3788/4885ALDH1A1 2090/4885CYP3A4 1560/4885 |
| US-12391683-B2 | Therapeutic compounds and methods | TRPV4, TRPV3, TRPV2 | CYP2C19 3788/4885ALDH1A1 2090/4885CYP3A4 1560/4885 |
| US-20240076294-A1 | THERAPEUTIC COMPOUNDS AND METHODS | TRPV4, TRPV3, TRPV2 | CYP2C19 3788/4885ALDH1A1 2090/4885CYP3A4 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.